NCI R01 – Novel TYRO3 inhibitors for treatment of cancer
Eschelman Institute for Innovation – Novel TYRO3 degraders for treatment of cancer
Donaldson Charitable Trust – Targeting MERTK to improve immunotherapeutic response in NSCLC
CURE Childhood Cancer – Development of AML bone marrow organoids for pediatric precision medicine applications.
NCI R01 – Development of dual MERTK and AXL inhibitors